Ignite a New Approach
to Cancer Care

ImmunoGenesis brings a clear and singular focus to the complex realm of cancer treatment. We are developing science-driven immunotherapies specifically designed to treat tumors lacking activated T cells or having other immune resistance mechanisms. Because these “cold” tumors are resistant to existing immunotherapy, our team is striving to create sophisticated therapies that target key mechanisms of immune resistance.

We are approaching treatment for cold tumors through a new lens, re-envisioning treatment with a deliberate drug development strategy based in cold tumor pathology.

A team with vision
The skills to deliver

We understand cold tumors and their resistance pathways. Our team is using rational design to address resistance mechanisms and empower the immune system to target tumors. We’re bringing the sauce.

Explore our ethos

We understand cold tumors and their immune resistance pathways. Our team is using rational design to address resistance mechanisms and empower the immune system to target tumors. We’re bringing the sauce.

Re-envision Cold Tumor Treatment

Our novel PD-L1/PD-L2 dual-specific inhibitor is a platform molecule around which several promising treatments for cold tumors can be built. This is the first antibody to target PD-L2. This vision puts ImmunoGenesis at the forefront of scientific exploration.

Built utilizing our platform, our lead asset was engineered with robust effector function. Another PD-L1/PD-L2 antibody from this platform is being developed as a tumor-selective delivery vehicle for our potent stimulator of interferon genes (STING) agonist.

Our programs address key processes underlying difficult-to-treat cold tumor pathology.

Check out our timing

Our foundation


Foundational to our vision is a first‑in‑class PD‑L1/PD‑L2 dual‑specific antibody.

PD‑1 suppresses T‑cell activation through binding its ligands, PD‑L1 and PD‑L2. PD‑L2 is a critical regulator of human tumor immunity. Pairing it with the known action of the PD‑L1 inhibitor means the platform, at minimum, offers the same blocking function as a PD‑1 inhibitor. Building on that action, we are designing it with effector function, which allows the antibody to kill the immunosuppressive cells in the tumor microenvironment. Additionally, the antibody may also function as a tumor‑specific delivery vehicle and as the base for dual‑specific programs, expanding targeting options.

For design and creation, we partnered with a novel antibody development company. Through trial and error and multiple rounds of affinity maturation, we developed a novel antibody in which both arms bind with clinically relevant affinities to both PD‑L1 and PD‑L2.

Our lead


IMGS-001 re‑envisions the starting point for cold tumor treatment with a novel, dual‑specific PD‑L1/PD‑L2 inhibitor engineered with effector function. This means we are addressing tumor pathology at the roots. Rather than building on the fragile 5% response rate seen with PD‑L1 inhibition in cold tumors, we are developing a foundation of PD‑1 pathway blockade. Based on the results of preclinical studies, we believe IMGS‑001 has the potential to increase the cold tumor monotherapy response rate >5x the efficacy of current PD‑1 pathway inhibitors.

Deliver potent STING agonist


IMGS-501, our STING‑mAb Immune Stimulating Antibody Conjugate (ISAC), builds on the novel PD‑L1/PD‑L2 dual‑specific inhibitor platform by conjugating a STING agonist to the antibody. This design combines a tumor‑specific transport vehicle in the PD‑L1/PD‑L2 dual‑specific antibody with a powerful immune agonist. We are developing ISAC to effectively and systemically transport the STING agonist to all tumor sites and to the right cells within the tumor microenvironment. This therapeutic advance pushes through an important barrier seen with traditional STING agonists, which consistently produce an effect only at the site of the intratumoral injection. Our STING agonist can be administered intravenously and delivered by the antibody precisely where it is most effective across tumor sites.



Cancer Care

Unlock the potential of immunotherapy for more patients.



Cancer Care

Unlock the potential of immunotherapy for more patients.

Cautious estimates hint at a market greater than $50 billion.

With 1.8 million cases of cancer every year and 55% of those being cold tumors, this treatment category presents significant opportunity.


With a secure manufacturability profile and a highly defensible IP position, early conversations with the FDA, and solid clinical trial plans, we are well positioned and ready to enter the clinic.

Learn more

Our Latest News

ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced Solid Tumors

September 28, 2023

Read more
ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors

June 27, 2023

Read more
ImmunoGenesis to Present Pre-Clinical Data from Lead Program at Society for Immunotherapy of Cancer Conference

November 3, 2022

Read more

Recent Publications

Development of IMGS-001, a novel anti–PD-L1/PD-L2 dual-specific, multifunctional antibody, to treat immune-excluded tumors.

SITC Annual Meeting

November 8-12, 2022

View poster
Preclinical characterization of IMGS-001, a dual-antagonist anti–PD-L1 and PD-L2 antibody with effector function, to treat patients resistant to immune checkpoint blockade.

SITC Annual Meeting

November 8-12, 2022

View poster